Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 24, Issue 12, 2008, Pages 1477-1484

  Resino, Salvador ^a,b   Micheloud, Dariela ^b   Larrú, Beatriz ^a   Bellón, Jose M ^a   Léon, Juan Antonio ^c   Resino, Rosa ^a   De José, M Isabel ^d   Gutiérrez, M Dolores Gurbindo ^a   Mellado, M José ^d   Guillen, Sara ^e   Ramos, José Tomas ^e   Muñoz Fernández, M Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD CARE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 58149133693     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0037     Document Type: Article

References (37)

1. Sharland M, Blanche S, Castelli G, Ramos J, and Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004;5(Suppl. 2):61-86.
2. Resino S, Resino R, Micheloud D, et al.: Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 2006;42:862-869.
3. Nikolic-Djokic D, Essajee S, Rigaud M, et al.: Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis 2002;185:290-298.
4. Soh CH, Oleske JM, Brady MT, et al.: Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003;362:2045-2051.
5. Group EPL: Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451.
6. Beregszaszi M, Dollfus C, Levine M, et al.: Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005;40:161-168.
7. Guillen S, Ramos JT, Resino R, Bellon JM, and Munoz MA: Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007;26:334-338.
8. Dzwonek AB, Lawson MS, Cole TJ, and Novelli V: Body fat changes and lipodystrophy in HIV-infected children: Impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:121-123.
9. Taylor P, Worrell C, Steinberg SM, et al.: Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004;114:e235-242.
10. Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006;43:645-653.
11. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, and Kline MW: Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21:405-410.
12. Resino S, Gurbindo M, Bellón J, Sanchez-Ramón S, and Muñoz-Fernández M: Predictive markers of clinical outcome in vertically HIV-1 infected infants. A prospective longitudinal study. Pediatr Res 2000;47:509-515.
13. CDCP: 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994;43:1-10.
14. CDC: Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47:1-43.
15. Resino S, Bellón J, Gurbindo D, et al.: Viral load and CD4+ T-cells response to HAART in HIV-infected children: An observational study. Clin Infect Dis 2003;37:1216-1225.
16. Sharland M, Gibb D, and Giaquinto C: Current evidence for the use of paediatric antiretroviral therapy - a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr 2000;159:649-656.
17. Sharland M, di Zub GC, Ramos JT, Blanche S, and Gibb DM: PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med 2002;3:215-226.
18. Hartman K, Verweel G, de Groot R, and Hartwig NG: Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:427-431.
19. Haynes BF, Markert ML, Sempowski GD, Patel DD, and Hale LP: The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000;18:529-560.
20. Resino S, Seoane E, Gutierrez MD, Leon JA, and Munoz-Fernandez MA: CD4(+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;42:269-276.
21. Resino S, Bellón J, Gurbindo D, and Muñoz-Fernández MA: CD38 in CD8+ T cells predict virological failure in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2004;38:412-417.
22. Paul ME, Mao C, Charurat M, et al.: Predictors of immunologic long-term nonprogression in HIV-infected children: Implications for initiating therapy. J Allergy Clin Immunol 2005;115:848-855.
23. Resino S, Galan I, Perez A, et al.: Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. AIDS Res Hum Retroviruses 2005;21:398-406.
24. Koletar SL, Williams PL, Wu J, et al.: Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis 2004;39:1500-1506.
25. Deeks SG, Barbour JD, Grant RM, and Martin JN: Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-207.
26. Le Moing V, Thiebaut R, Chene G, et al.: Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002;185:471-480.
27. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, and Cooper DA: The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002;16:359-367.
28. Tarwater PM, Margolick JB, Jin J, et al.: Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:168-175.
29. Resino S, Resino R, Maria Bellon J, et al.: Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006;43:243-252.
30. Jones SP, Qazi N, Morelese J, et al.: Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005;40:565-572.
31. Carter RJ, Wiener J, Abrams EJ, et al.: Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: A longitudinal analysis. J Acquir Immune Defic Syndr 2006;41:453-460.
32. Farley J, Gona P, Crain M, et al.: Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 2005;38:480-487.
33. Tershakovec AM, Frank I, and Rader D: HIV-related lipodystrophy and related factors. Atherosclerosis 2004;174:1-10.
34. American Academy of Pediatrics, Committee on Nutrition: Cholesterol in childhood. Pediatrics 1998;101:141-147.
35. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, and Levy J: Prevalence of lipodystrophy in HIV-infected children: A cross-sectional study. Eur J Pediatr 2007;166:13-21.
36. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, and Kuijpers TW: Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006;117:e528-536.
37. Domingo P, Matias-Guiu X, Pujol RM, et al.: Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999;13:2261-2267.